Given that PD-L1 expression in tumor tissue is an important biomarker that predicts clinical outcomes to anti–PD-1/PD-L1 treatment (11), it is possible that tumor tissue in EGFR-mutated NSCLC expresses low levels of PD-L1. This evidence concerns the gene CD274 and neoplasm.